Division Chief, Hematology-Oncology, Banner MD Anderson Cancer Center, Arizona
Oncology
Dr. Tomislav Dragovich, MD
|
|
Give Review
Doctor Tomislav Dragovich, MD practices Oncology. Tomislav Dragovich is also published. He has 29 publications published. The lastest publication: "Signal transduction pathways that regulate cell survival and cell death.' Tomislav Dragovich, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophage...
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
- Phase II trial of vatalanib in patients with advanced or metastatic Pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
- Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG...
- A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal Cancers.
- Is there a case for personalized therapy of pancreatic Cancer?
- A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancre...
- Emerging role of target-based therapies for gastrointestinal Malignancies.
- A case of fatal Rosai-Dorfman Syndrome in an adult; failure of multiple empiric therapies.
- Discrepancy in the assessment of tumor response in patients with pancreatic Cancer: WHO versus RECIST criteria.
- A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid Tumors.
- Signal transDuction pathways that regulate cell survival and cell death.
- Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques.
- Management strategies in pancreatic Cancer.
- A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced Cancer of the pancreas following progression after a gemcitabine-containing...
- A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive Pancreatic adenocarcinoma.
- Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.
- Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic Pancreatic adenocarcinoma carrying germline BRCA2 mutation.
- Bortezomib with or without irinotecan in relapsed or refractory coloRectal cancer: results from a randomized phase II study.
- Gemcitabine plus celecoxib in patients with advanced or metastatic Pancreatic adenocarcinoma: results of a phase II trial.
- A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
- Phase I trial of imexon in patients with advanced malignancy.
- A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid Tumors.
- Erlotinib plus gemcitabine in patients with unresectable pancreatic Cancer and other solid tumors: phase IB trial.
- Phase II trial of erlotinib in gastroEsophageal junction and gastric adenocarcinomas: SWOG 0127.
- A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced coloRectal cancer.
- The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in Cancer patient plasma.
- Stability of phosphoprotein as a biological marker of tumor signaling.
Schools
University of Belgrade
Louis a Weiss Meml Hospital
Louis a Weiss Memorial Hospital Internal Medicine
University Of Chicago Medical Center HematologyOncology
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Chicago -
University of Belgrade Faculty of Medicine
Drug Facts
| NPI NUMBER | 1518979715 | |
| NPPES Provider LastName | DRAGOVICH | |
| NPPES Provider FirstName | TOMISLAV | |
| NPPES Provider ZIPCode | 85234 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 284.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 10.21 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518979715 |
| Last Name Of The Provider | DRAGOVICH |
| First Name Of The Provider | TOMISLAV |
| View All |
Similar Doctors
|
Dr. Parminder Singh, MD |
|
|
Dr. Pavani Chalasani, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leona B. Downey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee D. Cranmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tenney B. Kentro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ursa A. Brown-Glaberman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faiz Anwer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen W. Renner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deborah A. Fuchs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mehrnoosh Zarkoob, MD |
|
|
Dr. Catherine A. Azar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald J. Brooks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucas Redd, MD |
|
|
Dr. Natalie A. Swansen, MD
This Doctor is OpenDoctor Recommended.
|